Advisory Committee on Immunization Practices, 121, 189, 213, 238, 278

Afebrile seizures, 53, 78, 144

Age-related effects

hepatitis B vaccination response, 214

in Hib vaccinations, 236-237, 240

Age-specific incidence, 17

in Guillain-Barré syndrome, 46-47

Aids to Interpretation of the Vaccine Injury Table, 48-49, 50

American Academy of Pediatrics, 121, 176, 189, 213, 238

Analytic bias, 21

Anaphylaxis, 26

causality, 16, 17, 108, 109, 175-176, 205, 230-231, 262-263

clinical description, 59-61, 100, 170, 204, 228, 261

diphtheria vaccination and, 17, 100-110, 288, 290

fatal outcomes, 170, 231, 261, 288, 290, 292, 294-295, 300

hepatitis B vaccination and, 17, 228-231, 300

Hib vaccination and, 262-263

measles-mumps-rubella vaccination and, 17, 170-176, 292

measles vaccination and, 16, 175, 292

mumps vaccination and, 176

polio vaccination and, 204-205

risk-modifying factors, 109, 176, 231

tetanus vaccination and, 17, 100-110, 290

Antibody-antigen reaction

in anaphylaxis, 60-61

in arthritis, 95

Arthus type, 61-62

in delayed-type hypersensitivity, 62

in hepatitis B serum-like sickness, 223-224, 227

in hepatitis B vaccine-induced anaphylaxis, 228-229

in Hib vaccination, 240-241, 251-253

in measles, 121-122

in normal tissue, 61

normative, 63

in tetanus vaccination, 70-71, 101

Arthralgia, 94, 222, 224, 226

Arthritis, 17

causality, 97, 226-227

clinical description, 94, 222

diphtheria-tetanus vaccination and, 95-97

epidemiology, 222

hepatitis B vaccination and, 223-227

Arthropathy, 222, 223, 224

Arthus reaction, 59, 61-62

in tetanus vaccination, 70-71

Aseptic meningitis, 49, 306

causality, 134-135

clinical description, 130

incidence, 130

mumps vaccination and, 130-135

Attributable risk, 27

B

B cells, 240, 241

Bayesian analysis, 25

Bias

analytic, 21

information, 21

systematic, 21

Biologic gradient, 21

Biologic plausibility, 5, 22

anaphylaxis, 101-104, 170-171, 228-229, 230, 262

arthritis, 95, 97, 223-224, 227

aseptic meningitis, 131, 134

demonstrated. 28

demyelinating diseases, 47-48, 84, 199, 220

diabetes mellitus, 155-156, 159

early-onset Hib disease, 251-252

encephalopathy, 73, 77, 123, 129

erythema multiforme, 98

evidentiary role of, 5, 28, 31, 32-33

Front Matter (R1-R16)

1 Executive Summary (1-18)

2 Causality and Evidence (19-33)

3 Neurologic Disorders (34-58)

4 Immunologic Reactions (59-66)

5 Diphtheria and Tetanus Toxoids (67-117)

6 Measles and Mumps Vaccines (118-186)

7 Polio Vaccines (187-210)

8 Hepatitis B Vaccines (211-235)

9 Haemophilus influenzae Type b Vaccines (236-273)

10 Death (274-304)

11 Need for Research and Surveillance (305-308)

APPENDIX A Executive Summary from Adverse Effects of Pertussis and Rubella Vaccines (309-317)

APPENDIX B Strategies for Gathering Information (318-334)

APPENDIX C Glossary (335-341)

APPENDIX D Committee and Staff Biographies (342-347)

Bibliography (348-450)

Index (451-464)